18,886 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Graham Capital Management L.P.

Graham Capital Management L.P. acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, HoldingsChannel.com reports. The firm acquired 18,886 shares of the biopharmaceutical company’s stock, valued at approximately $1,744,000.

A number of other institutional investors have also recently added to or reduced their stakes in GILD. Wealth Enhancement Advisory Services LLC increased its stake in Gilead Sciences by 0.5% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 324,469 shares of the biopharmaceutical company’s stock worth $29,971,000 after acquiring an additional 1,458 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in Gilead Sciences by 2.3% during the fourth quarter. Harbor Capital Advisors Inc. now owns 27,621 shares of the biopharmaceutical company’s stock worth $2,551,000 after acquiring an additional 616 shares during the last quarter. Czech National Bank increased its stake in Gilead Sciences by 6.5% during the fourth quarter. Czech National Bank now owns 270,216 shares of the biopharmaceutical company’s stock worth $24,960,000 after acquiring an additional 16,598 shares during the last quarter. Aprio Wealth Management LLC increased its stake in Gilead Sciences by 124.7% during the fourth quarter. Aprio Wealth Management LLC now owns 7,766 shares of the biopharmaceutical company’s stock worth $717,000 after acquiring an additional 4,310 shares during the last quarter. Finally, Matrix Trust Co increased its stake in Gilead Sciences by 515.2% during the fourth quarter. Matrix Trust Co now owns 1,052 shares of the biopharmaceutical company’s stock worth $97,000 after acquiring an additional 881 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. The Goldman Sachs Group raised their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research note on Thursday, February 13th. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, March 27th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, Oppenheimer dropped their price objective on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $110.55.

Gilead Sciences Trading Down 1.3%

GILD opened at $96.86 on Monday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The stock has a market capitalization of $120.61 billion, a price-to-earnings ratio of 261.78, a PEG ratio of 0.71 and a beta of 0.26. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The business has a fifty day moving average price of $107.23 and a 200 day moving average price of $99.39.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. During the same period in the previous year, the firm posted ($1.32) EPS. Gilead Sciences’s revenue for the quarter was down .3% on a year-over-year basis. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 3.26%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is 66.53%.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at $17,597,559.49. The trade was a 1.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 160,605 shares of company stock valued at $16,718,136 in the last ninety days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.